US-based biopharmaceutical company Clovis Oncology has announced the pricing for its proposed issue of convertible senior notes due 1 May 2025.

The company has simultaneously announced the issue of 1,837,898 shares priced at $54.41 a share in an underwritten public offering to raise $100m.

The underwriters have been granted a 30-day option to buy $45m-worth notes, and 275,684 additional shares.

Clovis Oncology plans to use the proceeds towards sales and marketing expenses of Rubraca (rucaparib) in the US.

The company appointed J. P. Morgan Securities and Merrill Lynch, Pierce, Fenner & Smith as joint book-running managers, and Willkie Farr & Gallagher as legal adviser for the transaction.

French pharmaceutical company Les Laboratoires Servier has agreed to purchase Shire’s oncology business for $2.4bn in a cash transaction.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The acquisition will enable Servier to further reinforce its portfolio and presence in the US.

The acquisition has been approved by the Shire board of directors.

Shire’s oncology products include ONCASPAR (pegaspargase), ONIVYDE (irinotecan pegylated liposomal formulation), for which the company owns ex-US rights, and Calaspargase Pegol (Cal-PEG).

German pharmaceutical and life sciences company Bayer intends to issue 31 million shares priced at €96.77 ($119.29) a share in a private placement to raise €3bn ($3.69bn). Temasek Holdings (Private) Ltd will subscribe to the placement.

Based in Singapore, Temasek Holdings will purchase 3.6% shared in Bayer, as part of the agreement.

Bayer plans to use the proceeds for the proposed Monsanto acquisition.

“French pharmaceutical company Les Laboratoires Servier has agreed to purchase Shire’s oncology business for $2.4bn in a cash transaction.”

Compagnie de Saint Gobain (Saint-Gobain) has acquired Micro Hydraulics’ pharmaceutical business with the aim of strengthening its high-performance materials activity and expanding its product and service offerings in the healthcare market.

Based in France, Saint-Gobain is a designer, manufacturer and distributor of building materials.

Based in Ireland, Micro Hydraulics provides single-use fluid handling components and systems in high-performance plastics for high-purity applications in the pharmaceutical and biopharmaceutical industries.

Apellis Pharmaceuticals has filed a registration statement with the US Securities and Exchange Commission (SEC) to issue five million shares of its common stock in order to raise funds required for business expansion, working capital and other general corporate purposes.

Priced at $26.73 a share, the issue will help raise $153.69m in gross proceeds.

The underwriter will receive a 30-day option to buy an additional 750,000 shares.

Based in the US, Apellis Pharmaceuticals is a pharmaceutical company.

Apellis Pharmaceuticals has appointed Citigroup Global Markets, J.P. Morgan Securities and Cowen and Company as financial advisers and Wilmer Cutler Pickering Hale and Dorr as legal adviser for the transaction.

Israeli speciality pharmaceutical company Foamix Pharmaceuticals has issued shares to OrbiMed Advisors in a direct offering to raise $16.17m.

Priced at $5.5 a share, the issue involved a total of 2.94 million shares.

The company has appointed Herzog, Fox & Neeman as legal adviser for the transaction.

South Korean biopharmaceutical company Alteogen has announced plans to issue shares in a private placement to raise funds required for operations and facilities.

The issue will include 1,090,280 preferred shares to raise KRW32bn ($29.88m) in gross proceeds.